Lv3
240 积分 2025-12-29 加入
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
12小时前
已完结
De-escalation trials in multiple myeloma: past, present and future
14天前
已完结
Impact of Treatment Sequencing with CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model
17天前
已完结
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
29天前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
1个月前
已完结
Challenges of Cellular Therapy During the COVID-19 Pandemic
1个月前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
2个月前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
2个月前
已完结
Challenges facing CAR T-cell immunotherapy in multiple myeloma
2个月前
已完结
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What’s the Current Status?
2个月前
已完结
皖公网安备34019202002308
